生命科学资讯

Senate HELP Committee chair pitches proposals for FDA reform

Blood from pediatricians yields potential new medicines for respiratory viruses

FDA accepts filing for Moderna flu vaccine after swift rethink

Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal

Sensei steps back from brink by finding Faeth and its phase 2-stage cancer drug

Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal

Danaher buys patient monitoring specialist Masimo in $9.9B deal

Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study

Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody

Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development

Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering

Boehringer axes inhaled gene therapy after viewing cystic fibrosis data

Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data

Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push

Cyrano noses toward pivotal trial after midphase smell loss win

Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer

Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse

Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments

FDA rejects Disc's rare disease drug despite commissioner's voucher